Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 2767-2768 [2022-00887]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
Note: The times and sequence specified in
this agenda are subject to change.
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
Authority: 16 U.S.C. 1801 et seq.
[RTID 0648–XB723]
Fisheries of the South Atlantic; South
Atlantic Fishery Management Council;
Public Meetings
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice of seminar series
presentation.
Dated: January 13, 2022.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2022–00907 Filed 1–18–22; 8:45 am]
BILLING CODE 3510–22–P
AGENCY:
The South Atlantic Fishery
Management Council (Council) will host
a presentation on working waterfront
infrastructure in Georgia via webinar.
DATES: The webinar presentation will be
held on Tuesday, February 8, 2022, from
1 p.m. until 2:30 p.m.
ADDRESSES:
Meeting address: The presentation
will be provided via webinar. The
webinar is open to members of the
public. Information, including a link to
webinar registration will be posted on
the Council’s website at: https://
safmc.net/safmc-meetings/othermeetings/ as it becomes available.
Council address: South Atlantic
Fishery Management Council, 4055
Faber Place Drive, Suite 201, N
Charleston, SC 29405.
FOR FURTHER INFORMATION CONTACT: Kim
Iverson, Public Information Officer,
SAFMC; phone: (843) 302–8439 or toll
free: (866) SAFMC–10; fax: (843) 769–
4520; email: kim.iverson@safmc.net.
SUPPLEMENTARY INFORMATION: The
Council will host a presentation from
Georgia Southern University on working
waterfronts in Georgia. The presentation
will describe available fishing
infrastructure in Georgia and the
industry members utilizing that
infrastructure. Information for the
project was collected through a census
of historic and current industry
infrastructure, case studies, spatial
analysis, a survey of seafood industry
participants, and in-depth interviews. A
question-and-answer session will follow
the presentation. Members of the public
will have the opportunity to participate
in the discussion. The presentation is
for informational purposes only and no
management actions will be taken.
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
Special Accommodations
The meeting is physically accessible
to people with disabilities. Requests for
auxiliary aids should be directed to the
Council office (see ADDRESSES) 5 days
prior to the meeting.
VerDate Sep<11>2014
16:58 Jan 18, 2022
Jkt 256001
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary
Advisory Panel; Notice of Federal
Advisory Committee Meeting
Under Secretary of Defense for
Personnel and Readiness, Department of
Defense (DoD).
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The DoD is publishing this
notice to announce that the following
Federal Advisory Committee meeting of
the Uniform Formulary Beneficiary
Advisory Panel (UFBAP) will take
place.
DATES: Open to the public on day 1 of
the meeting Tuesday, January 25, 2022,
10:00 a.m.–6:00 p.m. and on Day 2 of
the meeting January 26, 2022, 9:00 a.m.–
6:00 p.m. (Eastern Standard Time).
ADDRESSES: The meeting will be held
telephonically or via conference call.
The phone number for the remote access
on January 25–26, 2022 is: CONUS: 1–
888–946–3815; OCONUS: 1–415–228–
4881; PARTICIPANT CODE: 6978956.
These numbers and the dial-in
instructions will also be posted on the
Uniform Formulary Beneficiary
Advisory Panel website at: https://
www.health.mil/About-MHS/OASDHA/
Defense-Health-Agency/Operations/
Pharmacy-Division/BeneficiaryAdvisory-Panel.
FOR FURTHER INFORMATION CONTACT:
Colonel Paul J. Hoerner, USAF, 703–
681–2890 (Voice), dha.ncr.j6.mbx.baprequests@mail.mil (Email).
Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA
22042–5101. Website: https://
www.health.mil/About-MHS/OASDHA/
Defense-Health-Agency/Operations/
Pharmacy-Division/BeneficiaryAdvisory-Panel. The most up-to-date
changes to the meeting agenda can be
found on the website.
SUPPLEMENTARY INFORMATION: Due to
circumstances beyond the control of the
Department of Defense and the
Designated Federal Officer, the UFBAP
was unable to provide public
SUMMARY:
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
2767
notification required by 41 CFR 102–
3.150(a) concerning its January 25
through 26, 2022 meeting. Accordingly,
the Advisory Committee Management
Officer for the Department of Defense,
pursuant to 41 CFR 102–3.150(b),
waives the 15-calendar day notification
requirement. This meeting is being held
under the provisions of the Federal
Advisory Committee Act (FACA) (5
U.S.C., Appendix) and 41 CFR 102–
3.140 and 102–3.150. The Panel will
review and comment on
recommendations made to the Director,
Defense Health Agency, by the
Pharmacy and Therapeutics Committee,
regarding the Uniform Formulary.
Purpose of the Meeting: The DoD is
publishing this notice to announce that
the following Federal Advisory
Committee meeting of the Uniform
Formulary Beneficiary Advisory Panel
will take place.
Agenda Items
1. Day 1—January 25, 2022
a. 10:00 a.m.–10:10 a.m. Sign In for
UFBAP members
b. 10:10 a.m.–10:20 a.m. Welcome and
Opening Remarks by Col Paul J.
Hoerner, Designated Federal Officer
(DFO), UFBAP
c. 10:20 a.m.–10:30 a.m. Introduction of
UFBAP Members by Col Hoerner
d. 10:30 a.m.–10:45 a.m. Opening
Remarks by UFBAP Co-Chair Senior
Chief Petty Officer (Ret) Jon R.
Ostrowski, Non-Commissioned
Officers Association
e. 10:45 a.m.–11:00 a.m. Introductory
Remarks by CDR Scott Raisor,
Interim Chief, Formulary
Management Branch
2. Discussion of the February 2021 DoD
P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 11:00 a.m.–11:30 a.m. Breast Cancer
Agents: Cyclin Dependent Kinase
Inhibitors (LCDR Todd Hansen)
b. 11:30 a.m.–12:00 p.m. Pulmonary III
Agents (Dr. Angela Allerman)
c. 12:00 p.m.–1:00 p.m. Break for Lunch
d. 1:00 p.m.–1:45 p.m. Newly Approved
Drugs Review (Dr. Amy Lugo, and
other FMB staff, including CDR
Raisor, and MAJ Adam Davies)
e. 1:45 p.m.–2:45 p.m. Pertinent
Utilization Management Issues
(MAJ Davies, and other FMB staff,
including Dr. Allerman, and CDR
Raisor)
* Note that the UFBAP Discussion and
Vote will follow each section
f. 2:45 p.m.–3:00 p.m. Break
E:\FR\FM\19JAN1.SGM
19JAN1
2768
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
3. Discussion of the May 2021 DoD P&T
Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 3:00 p.m.–3:30 p.m. Menopausal
Hormone Therapy: Single Agents,
Combination Agents, and Vaginal
Agents (LCDR Elizabeth Hall)
b. 3:30 p.m.–4:00 p.m. Sleep Disorders:
Insomnia (Dr. Lugo)
c. 4:00 p.m.–4:45 p.m. Newly Approved
Drugs Review (Dr. Lugo, and other
FMB staff including, LCDR Hall,
MAJ Davies, LCDR Hansen, and Dr.
Allerman)
d. 4:45 p.m.–5:15 p.m. Pertinent
Utilization Management Issues
(MAJ Davies and other FMB staff
including Dr. Allerman, Dr. Lugo,
and LCDR Hall)
e. 5:15 p.m.–5:30 p.m. Re-evaluation of
Nonformulary generics (Dr.
Allerman)
* Note that the UFBAP Discussion and
Vote will follow each section
f. 5:30 p.m.–5:45 p.m. Closing Remarks
by Senior Chief Petty Officer (Ret)
Ostrowski
g. 5:45 p.m.–6:00 p.m. Closing Remarks
by Col Hoerner
Agenda Items
1. Day 2—January 26, 2022
a. 9:00 a.m.–9:10 a.m. Sign In for
UFBAP members
b. 9:10 a.m.–9:15 a.m. Welcome and
Opening Remarks by Col Hoerner
c. 9:15 a.m.–9:30 a.m. Opening Remarks
by Senior Chief Petty Officer (Ret)
Ostrowski
2. Discussion of the August 2021 DoD
P&T Committee Recommendations
jspears on DSK121TN23PROD with NOTICES1
Scheduled Therapeutic Class Reviews
a. 9:30 a.m.–10:00 a.m. Leukemia and
Lymphoma Agents, Burton
Tyrosine Kinase Inhibitors LCDR
Hansen)
b. 10:00 a.m.–10:30 a.m. LaxativeCathartics-Stool Softeners—Bowel
Preparations (Dr. Lugo)
c. 10:30 a.m.–10:45 a.m. Break
d. 10:45 a.m.–11:45 a.m. Newly
Approved Drugs Review (Dr. Lugo
and other FMB staff, including
LCDR Hall, LCDR Hansen, Dr.
Allerman, CDR Raisor, and MAJ
Davies)
e. 11:45 a.m.–12:45 p.m. Pertinent
Utilization Management Issues
(MAJ Davies and other FMB staff,
including Dr. Lugo, and CDR
Raisor)
f. 12:45 p.m.–1:00 p.m. Tier Co-Payment
Change for the Pulmonary III
Agents (CDR Raisor)
g. 1:00 p.m.–1:15 p.m. Brand over
Generic Authorization and Tier 1
VerDate Sep<11>2014
16:58 Jan 18, 2022
Jkt 256001
Co-Payment Change for the
Pulmonary Arterial Hypertension
Drugs (Dr. Allerman)
* Note that the UFBAP Discussion and
Vote will follow each section
h. 1:15 p.m.–2:15 p.m. Break for Lunch
3. Discussion of the November 2021
DoD P&T Committee Recommendations
Formulary Beneficiary Advisory Panel
members.
Dated: January 12, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register, Liaison
Officer, Department of Defense.
[FR Doc. 2022–00887 Filed 1–18–22; 8:45 am]
BILLING CODE 5001–06–P
Scheduled Therapeutic Class Reviews
a. 2:15 p.m.–3:00 p.m. Continuous
Glucose Monitoring Systems—
Therapeutic Agents (Dr. Lugo)
b. 3:00 p.m.–3:30 p.m. Immunological
Agents Miscellaneous—
Subcutaneous Immunoglobulins
(LCDR Hansen)
c. 3:30 p.m.–4:30 p.m. Newly Approved
Drugs Review (Dr. Lugo and other
FMB staff including LCDR Hansen,
LCDR Giao Phung, LCDR Hall, MAJ
Davies and Maj Angelina Escano)
d. 4:30 p.m.–4:45 p.m. Break
e. 4:45 p.m.–5:45 p.m. Pertinent
Utilization Management Issues
(MAJ Davies)
*Note that the UFBAP Discussion and
Vote will follow each section
f. 5:45 p.m.–5:55 p.m. Closing Remarks
by Senior Chief Petty Officer (Ret)
Ostrowski
g. 5:55 p.m.–6:00 p.m. Closing Remarks
by Col Hoerner
Meeting Accessibility: Pursuant to
section 10(a)(1) of the FACA and 41 CFR
102–3.140 through 102–3.165, and
subject to the availability of phone lines,
this meeting is open to the public.
Telephone lines are limited and
available to the first 220 people dialing
in. There will be 220 line total: 200
domestic and 20 international,
including leader lines.
Written Statements: Pursuant to 41
CFR 102–3.10, and section 10(a)(3) of
FACA, interested persons or
organizations may submit written
statements to the Uniform Formulary
Beneficiary Advisory Panel about its
mission and/or the agenda to be
addressed in this public meeting.
Written statements should be submitted
to the Uniform Formulary Beneficiary
Advisory Panel’s Designated Federal
Officer (DFO). The DFO’s contact
information can be found in the FOR
FURTHER INFORMATION CONTACT section of
this notice. Written comments or
statements must be received by the
Uniform Formulary Beneficiary
Advisory Panel’s DFO at least two (2)
calendar days prior to the meeting so
they may be made available to the
Uniform Formulary Beneficiary
Advisory Panel for its consideration
prior to the meeting. The DFO will
review all submitted written statements
and provide copies to all Uniform
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
DEPARTMENT OF EDUCATION
Request for Nominations: National
Committee on Foreign Medical
Education and Accreditation
(NCFMEA)
Department of Education,
National Committee on Foreign Medical
Education and Accreditation
(NCFMEA).
ACTION: Request for nominations for
appointment to serve on the National
Committee on Foreign Medical
Education and Accreditation
(NCFMEA).
AGENCY:
Secretary of Education,
Miguel A. Cardona, Ed.D., is seeking
nomination(s) of medical experts for
appointment to fill six vacant positions
for service as a member of the National
Committee on Foreign Medical
Education and Accreditation
(NCFMEA).
SUMMARY:
Nominations must be received
no later than Friday, February 18, 2022.
SUPPLEMENTARY INFORMATION:
NCFMEA’s Statutory Authority and
Function: The NCFMEA is authorized
per section 102 of the Higher Education
Act of 1965, as amended. The Secretary
of Education is required by the Higher
Education Act, as amended, to establish
a panel of medical experts who shall:
Evaluate the standards of accreditation
applied to foreign medical schools; and
determine the comparability of those
standards to standards for accreditation
applied to United States medical
schools. The NCFMEA shall be
comprised of 11 voting members each
appointed for a term of service as
determined by the Secretary of
Education. Due consideration shall be
given to the appointment of individuals
who are broadly knowledgeable about
foreign medical education and
accreditation and respected in the
educational community. Per the
authorizing legislation for the
Committee, one currently serving
member of the NCFMEA, is a medical
student enrolled in an accredited
medical school at the time of
appointment by the Secretary of
Education.
DATES:
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 87, Number 12 (Wednesday, January 19, 2022)]
[Notices]
[Pages 2767-2768]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00887]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UFBAP) will take place.
DATES: Open to the public on day 1 of the meeting Tuesday, January 25,
2022, 10:00 a.m.-6:00 p.m. and on Day 2 of the meeting January 26,
2022, 9:00 a.m.-6:00 p.m. (Eastern Standard Time).
ADDRESSES: The meeting will be held telephonically or via conference
call. The phone number for the remote access on January 25-26, 2022 is:
CONUS: 1-888-946-3815; OCONUS: 1-415-228-4881; PARTICIPANT CODE:
6978956.
These numbers and the dial-in instructions will also be posted on
the Uniform Formulary Beneficiary Advisory Panel website at: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel.
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), [email protected] (Email). Mailing
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA
22042-5101. Website: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel.
The most up-to-date changes to the meeting agenda can be found on the
website.
SUPPLEMENTARY INFORMATION: Due to circumstances beyond the control of
the Department of Defense and the Designated Federal Officer, the UFBAP
was unable to provide public notification required by 41 CFR 102-
3.150(a) concerning its January 25 through 26, 2022 meeting.
Accordingly, the Advisory Committee Management Officer for the
Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-
calendar day notification requirement. This meeting is being held under
the provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C.,
Appendix) and 41 CFR 102-3.140 and 102-3.150. The Panel will review and
comment on recommendations made to the Director, Defense Health Agency,
by the Pharmacy and Therapeutics Committee, regarding the Uniform
Formulary.
Purpose of the Meeting: The DoD is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
Agenda Items
1. Day 1--January 25, 2022
a. 10:00 a.m.-10:10 a.m. Sign In for UFBAP members
b. 10:10 a.m.-10:20 a.m. Welcome and Opening Remarks by Col Paul J.
Hoerner, Designated Federal Officer (DFO), UFBAP
c. 10:20 a.m.-10:30 a.m. Introduction of UFBAP Members by Col Hoerner
d. 10:30 a.m.-10:45 a.m. Opening Remarks by UFBAP Co-Chair Senior Chief
Petty Officer (Ret) Jon R. Ostrowski, Non-Commissioned Officers
Association
e. 10:45 a.m.-11:00 a.m. Introductory Remarks by CDR Scott Raisor,
Interim Chief, Formulary Management Branch
2. Discussion of the February 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 11:00 a.m.-11:30 a.m. Breast Cancer Agents: Cyclin Dependent Kinase
Inhibitors (LCDR Todd Hansen)
b. 11:30 a.m.-12:00 p.m. Pulmonary III Agents (Dr. Angela Allerman)
c. 12:00 p.m.-1:00 p.m. Break for Lunch
d. 1:00 p.m.-1:45 p.m. Newly Approved Drugs Review (Dr. Amy Lugo, and
other FMB staff, including CDR Raisor, and MAJ Adam Davies)
e. 1:45 p.m.-2:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies, and other FMB staff, including Dr. Allerman, and CDR Raisor)
* Note that the UFBAP Discussion and Vote will follow each section
f. 2:45 p.m.-3:00 p.m. Break
[[Page 2768]]
3. Discussion of the May 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 3:00 p.m.-3:30 p.m. Menopausal Hormone Therapy: Single Agents,
Combination Agents, and Vaginal Agents (LCDR Elizabeth Hall)
b. 3:30 p.m.-4:00 p.m. Sleep Disorders: Insomnia (Dr. Lugo)
c. 4:00 p.m.-4:45 p.m. Newly Approved Drugs Review (Dr. Lugo, and other
FMB staff including, LCDR Hall, MAJ Davies, LCDR Hansen, and Dr.
Allerman)
d. 4:45 p.m.-5:15 p.m. Pertinent Utilization Management Issues (MAJ
Davies and other FMB staff including Dr. Allerman, Dr. Lugo, and LCDR
Hall)
e. 5:15 p.m.-5:30 p.m. Re-evaluation of Nonformulary generics (Dr.
Allerman)
* Note that the UFBAP Discussion and Vote will follow each section
f. 5:30 p.m.-5:45 p.m. Closing Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
g. 5:45 p.m.-6:00 p.m. Closing Remarks by Col Hoerner
Agenda Items
1. Day 2--January 26, 2022
a. 9:00 a.m.-9:10 a.m. Sign In for UFBAP members
b. 9:10 a.m.-9:15 a.m. Welcome and Opening Remarks by Col Hoerner
c. 9:15 a.m.-9:30 a.m. Opening Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
2. Discussion of the August 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 9:30 a.m.-10:00 a.m. Leukemia and Lymphoma Agents, Burton Tyrosine
Kinase Inhibitors LCDR Hansen)
b. 10:00 a.m.-10:30 a.m. Laxative-Cathartics-Stool Softeners--Bowel
Preparations (Dr. Lugo)
c. 10:30 a.m.-10:45 a.m. Break
d. 10:45 a.m.-11:45 a.m. Newly Approved Drugs Review (Dr. Lugo and
other FMB staff, including LCDR Hall, LCDR Hansen, Dr. Allerman, CDR
Raisor, and MAJ Davies)
e. 11:45 a.m.-12:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies and other FMB staff, including Dr. Lugo, and CDR Raisor)
f. 12:45 p.m.-1:00 p.m. Tier Co-Payment Change for the Pulmonary III
Agents (CDR Raisor)
g. 1:00 p.m.-1:15 p.m. Brand over Generic Authorization and Tier 1 Co-
Payment Change for the Pulmonary Arterial Hypertension Drugs (Dr.
Allerman)
* Note that the UFBAP Discussion and Vote will follow each section
h. 1:15 p.m.-2:15 p.m. Break for Lunch
3. Discussion of the November 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 2:15 p.m.-3:00 p.m. Continuous Glucose Monitoring Systems--
Therapeutic Agents (Dr. Lugo)
b. 3:00 p.m.-3:30 p.m. Immunological Agents Miscellaneous--Subcutaneous
Immunoglobulins (LCDR Hansen)
c. 3:30 p.m.-4:30 p.m. Newly Approved Drugs Review (Dr. Lugo and other
FMB staff including LCDR Hansen, LCDR Giao Phung, LCDR Hall, MAJ Davies
and Maj Angelina Escano)
d. 4:30 p.m.-4:45 p.m. Break
e. 4:45 p.m.-5:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies)
*Note that the UFBAP Discussion and Vote will follow each section
f. 5:45 p.m.-5:55 p.m. Closing Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
g. 5:55 p.m.-6:00 p.m. Closing Remarks by Col Hoerner
Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and
41 CFR 102-3.140 through 102-3.165, and subject to the availability of
phone lines, this meeting is open to the public. Telephone lines are
limited and available to the first 220 people dialing in. There will be
220 line total: 200 domestic and 20 international, including leader
lines.
Written Statements: Pursuant to 41 CFR 102-3.10, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the Uniform Formulary Beneficiary Advisory Panel
about its mission and/or the agenda to be addressed in this public
meeting. Written statements should be submitted to the Uniform
Formulary Beneficiary Advisory Panel's Designated Federal Officer
(DFO). The DFO's contact information can be found in the FOR FURTHER
INFORMATION CONTACT section of this notice. Written comments or
statements must be received by the Uniform Formulary Beneficiary
Advisory Panel's DFO at least two (2) calendar days prior to the
meeting so they may be made available to the Uniform Formulary
Beneficiary Advisory Panel for its consideration prior to the meeting.
The DFO will review all submitted written statements and provide copies
to all Uniform Formulary Beneficiary Advisory Panel members.
Dated: January 12, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register, Liaison Officer, Department of Defense.
[FR Doc. 2022-00887 Filed 1-18-22; 8:45 am]
BILLING CODE 5001-06-P
